![…a word from the Chairperson ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Más contenido relacionado
La actualidad más candente
La actualidad más candente (20)
Destacado
Destacado (17)
Similar a Fogsi Msd Protecting Young Girls
Similar a Fogsi Msd Protecting Young Girls (17)
Más de Shambhu N
Más de Shambhu N (18)
Último
Último (20)
Fogsi Msd Protecting Young Girls
- 1. PROTECTING YOUNG GIRLS An Educational Project by Adolescent Health Committee of FOGSI
- 3. FOGSI at a glance Federation of Obstetrics & Gynaecological Societies of India Health Care, Academics Research, Health Education Social Service >26 Committees (Like AHC ) >23,000 Members >200 Societies in 200 cities National Body of Women Health Care Providers
- 4. Overview of this presentation Preventive Health Objectives of Committee Social Health Effects of HPV infection on health HPV Vaccine Spiritual Health Protecting Young Girls B E C D A
- 5. Preventive Health Objectives of the Committee Social Health Effects of HPV infection on health HPV Vaccine Spiritual Health Protecting Young Girls B E C D A
- 8. Preventive Health Objectives of Committee Social Health Effects of HPV infection on health HPV Vaccine Spiritual Health Social health Protecting Young Girls B E C D A
- 11. Teens want Social health Encourage & praise Recognition Talk to them Communication & Confidentiality Share their feelings Empathy Beware of comparison Acceptance See strong/weak points objectively Understanding To be loved Affection Feeling of being wanted Security
- 12. Let’s talk… about Every teenager has a query & confusion! Let’s know…What are they?! Social health
- 13. Mom’s reactions! Look at her… How she treats me after all, I have done so much for her. . . She was NEVER like this before. . . Social health
- 14. Daughter’s reactions! No one understands me well. . My parents scolds me every now & then, they don’t love me. . . Social health
- 21. Adolescent’s emotions ~ Global concern Multiple / overlapping Social health ???? Insecurity Drive for freedom Fear Anger Peer pressure Frustration
- 23. Preventive Health Objectives of Committee Social Health Effects of HPV infection on health HPV Vaccine Spiritual Health Protecting Young Girls B E C D A
- 30. The next speaker will talk about Preventive Health Objectives of Committee Social Health Effects of HPV infection on health HPV Vaccine Spiritual Health Protecting Young Girls B E C D A
- 31. Preventive Health Objectives of Committee Social Health Effects of HPV infection on health HPV Vaccine Spiritual Health Protecting Young Girls B E C D A
- 43. Acne / Pimples Obesity/Overweight 50% of women with PCOS are obese. Which develops at the time of puberty . Polycystic Ovarion Disease It’s natural, normal reaction due to hormone changes…. Preventive health Pimples on face…. I really don’t like it! Oh! NO!!!
- 50. Preventive Health Objectives of Committee Social Health Effects of HPV infection on health HPV Vaccine Spiritual Health Protecting Young Girls B E C D A
- 52. The Big Boss From Smile to Agony
- 53. India ~1,32,000 World ~ 4,93,000 India ~27% of new Cancer cervix cases in world India ~ 74,000 World ~ 2,73,000 India ~27% Rest of World - 73% India ~ 27% of deaths due to Cancer cervix in world Rest of World - 73% India - 27% Cancer Cervix– Disease Burden New Cancer Cervix Cases Deaths due to Cancer Cervix India ~27% Rest of World - 73% India: ~27% deaths worldwide due to Cancer cervix WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in India. 2007. [Accessed on 18th March 2008. Available at www. who. int/ hpvcentre c WHO/ICO Information Centre on HPV and Cervical Cancer
- 54. *Ray K et al, Indian J Med Res 2006; 124: 559-568 18% 6% 11% 10.5% 0 2 4 6 8 10 12 14 16 18 20 1990-93 1994-97 1998-01 2002-04 Study Period Percentage Genital Warts – Disease Burden: India* Increasing trend of HPV induced Genital warts in India
- 55. Years of Life Lost to Cancer Cervix* *In women in the United States (2003) 1. Ries LAG, Harkins D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975–2003 , National Cancer Institute. Bethesda, MD; 2006. 26 19 18 26 Average years of life lost in women with Cancer cervix
- 56. HPV Infection Low Grade Cancerous Lesions High Grade Cancerous Lesions Invasive Cancer 0–1 Year 0–5 Years 1–20 Years Facts about HPV Infection Aim is to prevent High grade cancerous lesions Minimal symptoms Symptoms appear
- 57. Human Papillomavirus (HPV) HPV 16 HPV 18 HPV 6 HPV 11 Cancer causing Type 1,2,3 Non-cancer causing type 1,2 76.7% of cancer cervix cases in India 4 90% of anogenital wart cases worldwide 4 HPV 1.Schiffman M, Castle PE. Arch Pathol Lab Med . 2003;127:930–934. 2. Wiley DJ, Douglas J, Beutner K, et al. Clin Infect Dis . 2002;35(suppl 2):S210–S224. 3. Walboomers JM, Jacobs MV, Manos MM, et al. J Pathol. 1999;189:12–19. 4. X. Castellsagué, S. de Sanjose, T. Aguado, K. S. Louie, L. Bruni, J.Muñoz, M. Diaz, K. Irwin, M. Gacic, O. Beauvais, G. Albero, E. Ferrer, S. Byrne,F. X. Bosch. HPV and Cervical Cancer in the World. 2007 Report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Available at: www.who.int/hpvcentre HPV causes 99.7% cases of cancer cervix 3
- 60. Genital Warts 2 Vulvar/ Vaginal Precancers (Grade 1- 3) 2 Cancer Cervix & Precancers (Grade 2/ 3) 1 100% 98% 100% HPV induced cancers Protection by QHPV 1. The Future II Study Group. Lancet 2007; 369: 1861–68 2. Garland SM et al. New Engl J Med . 2007;356:1928–1943. Efficacy of Quadrivalent HPV Vaccine Quadrivalent vaccine is safe & highly efficacious
Notas del editor
- India’s population is approximately 1/6 th of the world burden but the disease burden in India is more than 25%( 1/4 th )
- Key Point Because HPV infection is common and usually asymptomatic, most transmission may occur unknowingly. HPV infection is usually transmitted by sexual contact, commonly through sexual intercourse, although transmission can occur through nonpenetrative genital contact. Background The greatest behavioral risk for the acquisition of HPV infection is sexual contact, specifically the rate of new partners per month. 1,2 Sexual intercourse is important in the transmission of HPV. 2 Other types of genital contact (genital–genital, manual–genital, oral–genital), which may begin at an earlier age than penetrative intercourse, may also lead to HPV infection. 1,3,4 A recent US study of 603 college-aged (19 years of age, average age at enrollment) women reported a 2-year genital HPV incidence rate of 39% among sexually active women and 8% among virginal women. 1 Genital HPV infection in virgins is rare, but may result from nonpenetrative sexual contact. 1 Proper condom use may help reduce the risk of genital warts, CIN 2 or CIN 3, and invasive cervical cancer, but is not fully protective against infection. 5 Other nonsexual routes of HPV infection include vertical transmission (from a mother to a newborn baby), although this is rare. 6 A potential consequence of vertical transmission of HPV is recurrent respiratory papillomatosis (RRP), epithelial growths in the respiratory tract. In the larynx, growths may cause hoarseness and airway obstruction, which is potentially fatal. This condition presents most often in children younger than 5 years of age; but it can also occur in adults. 7 Transmission of HPV infection may occur via contact with fomites, such as undergarments, surgical gloves, and biopsy forceps. This route of transmission has been hypothesized but is not well documented and would be rare. 8,9 Although it is clear that sexual contact is the major mode of HPV transmission, most individuals infected by HPV do not know they have the disease. 10 Therefore, they may unknowingly spread the virus. References 1. Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol . 2003;157:218–226. 2. Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: Evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev . 2001;10:101–106. 3. Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM. Hand–genital transmission of genital warts? An analysis of prevalence data. Epidemiol Infect . 1995;115:169–176. 4. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst . 2003;95:1772–1783. 5. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis . Sex Transm Dis . 2002;29:725−735. 6. Smith EM, Ritchie JM, Yankowitz J, et al. Human papillomavirus prevalence and types in newborns and parents: Concordance and modes of transmission. Sex Transm Dis . 2004;31:57–62. 7. Kashima HK, Mounts P, Shah K. Recurrent respiratory papillomatosis. Obstet Gynecol Clin North Am . 1996;23:699–706. 8. Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstet Gynecol . 1989;74:950–954. 9. Roden RB, Lowy DR, Schiller JT. Papillomavirus is resistant to desiccation. J Infect Dis . 1997;176:1076–1079. 10. Anhang R, Goodman A, Goldie SJ. HPV communication: Review of existing research and recommendations for patient education. CA Cancer J Clin. 2004;54:248 – 259.
- Key Point The Phase III clinical program for QHPV Vaccine ® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] includes FUTURE I and FUTURE II studies that enrolled more than 17,000 adolescent and young adult females (15 to 26 years old) on 4 continents (26 countries) and demonstrated 98% to 100% efficacy against Cervical precancers and genital warts. Background FUTURE I is a double-blind, placebo-controlled, randomized trial, for which 5,455 women aged 16 to 24 were enrolled across 62 study sites within 17 countries (4 continents), between January 2002 and March 2003. The enrolled population of young women was diverse and came from both developed and developing countries. The study covered a span of 4 years (data were unblinded June 15, 2006) and the average follow-up for the participants was 3 years. 1 The efficacy against HPV 6, 11, 16 & 18 related CIN 2/3, vulvar and Vaginal precancers and genital warts was found to be 100% FUTURE II is a double-blind, placebo-controlled randomized trial, for which 12,167 women aged 15 to 26 were enrolled across 90 study sites within 14 countries (4 continents), between June 2002 and May 2003. The study covered a span of 4 years (data were unblinded June 15, 2006) and the average follow-up for the participants was 3 years. 2 The efficacy against HPV 16 & 18 related CIN2/3 was 100% References: 1. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent HPV 6/11/16/18 vaccine: prevention of cervical, vulvar and vaginal disease. New Engl J Med . 2007;356: 1928–1943. 2. The FUTURE II Study Group. Quadrivalent HPV vaccine: prevention of high grade cervical intraepithelial neoplasia. New Engl J Med . 2007;356:1915–1927.